Have you or your loved ones been diagnosed with basal ganglia glioma?

You may be eligible to participate in a basal ganglia glioma clinical trial.

Have you or your loved ones been diagnosed with basal ganglia glioma? You may be eligible to participate in a basal ganglia glioma clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Recruiting for this study? Get access to patient recruitment tools.
Glioblastoma (GBM) and H3 K27M-mutant Glioma
NCT02525692 | Phase 2 | Interventional
Oncoceutics Inc
Sponsored by
Oncoceutics Inc

Have you or your loved ones been diagnosed with basal ganglia glioma?

You may be eligible to participate in a basal ganglia glioma clinical trial.

Have you or your loved ones been diagnosed with basal ganglia glioma? You may be eligible to participate in a basal ganglia glioma clinical trial.

Recruiting

Male & Female

16 Years +

This study is looking to recruit 76 Participants

ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients. This clinical trial will enroll patients with recurrent glioblastoma or recurrent WHO Grade IV gliomas with the H3 K27M mutation.

Available locations
Dana Farber Cancer Institute

Dana Farber Cancer Institute

Recruiting 450 Brookline Avenue, Boston, MA, USA 02115

Massachusetts General Hospital

Massachusetts General Hospital

Recruiting 15 Parkman Street, Boston, MA, USA 02114

University of California Los Angeles

University of California Los Angeles

Recruiting Los Angeles, CA, USA 90024

Miami Cancer Institute

Miami Cancer Institute

Recruiting 8900 North Kendall Drive, Miami, FL, USA 33176

Interested in learning more?
Oncoceutics Inc
Sponsored by Oncoceutics Inc

To get started, please choose a location